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Purpose: The ARIBON trial is a double blind, randomised, placebo controlled study designed to evaluate
the impact of ibandronate on bone mineral density (BMD) in women taking anastrozole for adjuvant
treatment of breast cancer.
Methods: 131 postmenopausal women with early breast cancer were recruited to the study. Of these,
13 had osteoporosis, 50 osteopenia and 68 normal BMD. Patients with osteoporosis at baseline were
treated with monthly oral ibandronate 150 mg for 5 years; osteopenic patients were randomised to
receive either ibandronate or placebo for two years and offered open label ibandronate depending upon
the results of their 2-year BMD result.
Results: Of the 20 patients with osteopenia who were randomised to ibandronate and evaluable at the
2 year visit, 17/20 were not offered a bisphosphonate and the improvements in BMD accrued during the
ﬁrst 2 years were lost both at the LS (3.21%) and TH (5.0%). Of the 16 patients randomised to
placebo 8/16 with high rates of bone loss during years 0–2 received ibandronate over the next 3 years
with improvements in BMD of þ5.01 and þ1.19 at the LS and TH respectively. The 8 patients who were
not offered a bisphosphonate experienced relatively little change in BMD throughout the 5 years of the
study (LS þ0.15%, TH 2.72%). BMD increased steadily in the 9/13 patients initially identiﬁed as having
osteoporosis (LS þ9.65%, TH þ2.72%).
Conclusions: Monthly oral ibandronate provides an option to clinicians considering use of a bispho-
sphonate to prevent bone loss during aromatase inhibitor therapy.
& 2012 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Following the results of several large randomised trials of
endocrine treatment strategies, adjuvant treatment with an aro-
matase inhibitor (AI) has become part of standard care for most
post-menopausal patients with oestrogen receptor positive (ERþ)
breast cancer [1–5]. Whilst the side effect proﬁle of AIs is generally
favourable in comparison to tamoxifen, with fewer thrombo-
embolic and gynaecological adverse events, musculoskeletal side
effects including accelerated bone loss and arthralgias are more
frequent with the AIs.
In the ATAC trial bone sub-protocol, patients treated with
anastrozole lost on average 2.3%, 4.0% and 6.1% bone mineral
density (BMD) at the lumbar spine (LS) and 1.5%, 3.9% and 7.2% at
the hip (TH) after 1, 2 and 5 years respectively (po0.001) [6]. This. This is an open access article un
).degree of bone loss is much higher than the normal rate of decline
in postmenopausal women of 0.6–1.0% per year [7]. Similar
effects have been seen with letrozole [8] and exemestane [9].
Additionally, the effects of AIs on bone turnover and the asso-
ciated increased bone loss results in a 40–50% increase in on
treatment fracture rate compared to the use of tamoxifen [10]. In
order to prevent clinically important adverse bone events, a
number of guidelines have been developed providing advice on
how to monitor patients, assess the risk of fragility fractures and
treat at risk patients with bone targeted drugs to prevent bone
loss [11–14].
Bisphosphonates are the cornerstone of management in post-
menopausal osteoporosis with randomised trial evidence of
reductions in vertebral fractures for ibandronate [15] and both
vertebral and non-vertebral fracture rates for alendronate [16],
risedronate [17], and zoledronic acid [18]. Ibandronate is a highly
potent nitrogen containing bisphosphonate that can be adminis-
tered both intravenously and orally. Using the oral route of
administration, a single dose every month in post menopausalder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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turnover markers as daily treatment [19]. This simple treatment
is potentially highly attractive for cancer patients and offers an
alternative to 6 monthly intravenous treatment with zoledronic
acid [20–21] or weekly oral therapy with risedronate [22].
Given the concerns about the long-term effects of anastrozole
on bone health, the ARIBON study was designed to evaluate the
effect of bisphosphonate treatment on patients considered at risk
for the development of osteoporosis during 5 years of anastrazole
therapy. The 2-year results have been published previously [23]
and showed that oral ibandronate was able to prevent bone loss
and reduce markers of bone turnover in patients with osteopenia
and osteoporosis. Here we present the ﬁnal 5 year study results.2. Methods
131 postmenopausal women with a histologically conﬁrmed
diagnosis of oestrogen receptor positive breast cancer from two
cancer centres (Shefﬁeld and Leeds) were recruited. Details of
the study eligibility and methods have been published previously
[23]. Brieﬂy, patients were excluded if menopause had been
induced by either prior chemotherapy or drug therapy (e.g.
goserelin). Other exclusion criteria included concurrent adminis-
tration of medications with effects on bone, abnormal renal
function, disorders of bone metabolism and previous bilateral
hip fractures or bilateral hip prostheses that would have hindered
reliable BMD assessments.
Following informed consent, patients underwent a baseline
assessment of BMD at the LS and TH before commencing
anastrozole and study entry. All patients received anastrozole
1 mg once a day and calcium (500 mg) and vitamin D (400 IU)
supplements daily. Patients with normal BMD (T score 41 at
both the LS and TH) were allocated to an observation group with a
follow-up BMD assessment at 2 years. No further protocol-
directed follow-up of these patients after year 2 was required,
and they were treated according to current clinical guidelines
at the two participating institutions. Patients with osteoporosis
(T score o2.5 at either the LS or TH) received open label
ibandronate 150 mg every 28 day by mouth for the 5 years of the
study. Patients classiﬁed as osteopenic (T-scores of 42.5 and
o1.0 at either the LS and TH) were randomly assigned in a
double blind manner on a 1:1 basis to receive either ibandronate
tablets 150 mg every 28 day or placebo tablets of identical
appearance also every 28 day for two years. Ibandronate/placebo
capsules were taken in an upright position ﬁrst thing in the
morning on an empty stomach and washed down with 100 mls
water to minimise the risk of oesophageal irritation; no food or
drink (other than water) was consumed for at least 30 min after
taking the study medication.
LS and TH BMD scans were repeated after 1 year (1271
month), 2 years (2472 months) and 5 years (6072 months).
Throughout the study the same densitometer was used at each of
the two centres to optimise the accuracy of measurements. A
phantom spine was scanned on a minimum of three days per
week in each centre to ensure precision over time. T-score results
were calculated using the Lunar (DPX Series Operator’s Manual
1998) manufacturer’s reference ranges for the lumbar spine
(L2-L4) and the NHANES III reference range for the total hip
region.
Patients (n¼5) who developed osteoporosis whilst taking
ibandronate/placebo medication were un-blinded and offered
open label ibandronate treatment. After 2 years the randomised
treatment was stopped and the treating clinician, depending upon
the results of the BMD result at 2 years, offered treatment with
open label ibandronate.Local ethics committee approval was obtained at both centres
prior to commencing recruitment. The study was sponsored by
the University of Shefﬁeld, and funded through unrestricted
academic grants from both Roche and Astra Zeneca who also
provided ibandronate/placebo and anastrazole study medications
respectively. All data were held within the Cancer Clinical Trials
Centre at the University of Shefﬁeld. All analyses were performed
by the investigators. Neither pharmaceutical company had any
input into the analysis or reporting of results. The ARIBON study
is registered on the UK department of health national research
register. Publication ID N0276137347 (http://www.nrr.nhs.uk).3. Statistical power and analysis
A description of the statistical analysis of the study has been
published previously [23]. For the analysis of the results at the
5-year time point, comparisons were expressed graphically using
95% conﬁdence intervals. Statistical analysis was performed using
SPSS version 19.0.0, 2010.4. Results
Between December 2003 and October 2005, 131 postmeno-
pausal, surgically treated breast cancer patients were recruited
from oncology clinics in Leeds and Shefﬁeld, UK. A total of 50
recruited patients were identiﬁed as having osteopenia at the
time of the baseline scan. 68 had normal BMD and 13 had
osteoporosis prior to starting anastrozole. The CONSORT diagram
in Fig. 1 shows the disposition of patients at baseline and their
subsequent course on study. The baseline characteristics of the
patients recruited to the trial have been previously published
[23]. The median age of the study population was 64.8 years and
the stratiﬁcation factors (centre, time from menopause, previous
HRT and previous chemotherapy) for the randomised patients
were well balanced between the two treatment groups.5. BMD results
The BMD changes from baseline for the osteopenic and
osteoporotic patients are shown in Fig. 2a–c and Table 1.
Osteopenic patients (ibandronate group): Of the 20 patients
randomised to ibandronate and evaluable at the 2 year visit,
BMD increased in the majority (13/20) with a mean overall
increase in LS BMD of þ3.19%. In 17/20 patients initially rando-
mised to ibandronate with a mean T-score of 1.11 (range 0.0 to
2.2) at 2 years, study medication was stopped and the patients
followed up on anastrozole alone till year 5 because BMD T scores
were 42. The improvements in BMD accrued during the ﬁrst
2 years were lost at both the LS (3.21%) and TH (5.0%). As a
consequence, at 5 years, 14 patients had T-scores in the osteo-
penic range and one had an osteoporotic T-score. Of the three
offered an open label bisphosphonate for the remaining 3 years of
the study; at the 2 year visit, two of these patients had a T-score
of between 2 and 2.5 and in one the T-score was o2.5. In
these three patients, BMD increased in 2 and 1 and fell in 1 and
2 at the LS and TH respectively (Data not shown). Two patients
still had a T-score of o2.5 at LS and/or TH after 5 years of
ibandronate.
Osteopenic patients (placebo group): The mean change in LS
BMD at the 2 year time-point in the 16 patients who were
randomised to placebo and who remained on study until the 5
year visit was 4.52%. Eight patients with high rates of bone
loss during years 0–2 (LS 7.1%, TH 7.3%) and a BMD result
at 2 years showing either severe osteopenia (T-score o2.0 to
Postmenopausal 
Early Breast Cancer 
Oestrogen receptor positive 
N=131
Consent 
Baseline DXA scan
Osteopenia 
T-score >-2.5 and <-1.0 
N=50
Osteoporosis 
T-score <-2.5 
N=13
RANDOMISATION
Ibandronate
N=25
Placebo 
N=25
Discontinued patients 
(n=4) 
Vaginitis (n=1) 
Joint pains (n=1) 
Patient choice (n=2) 
Discontinued patients 
(n=6) 
>10% fall in BMD(n=2) 
Recurrent disease (n=2) 
Bowel carcinoma (n=1) 
CVA (n=1)
Iyr BMD
2yr BMD
5yr BMD
Treatment 
2-5yrs
N=23 N=25
N=21 N=19
Ibandronate No BP Ibandronate No BP
Discontinued patients 
(n=2) 
Patient choice (n=2)
N=11
N=12
N=3 N=17 N=8 N=9
Ibandronate for 
5yrs
Discontinued patients 
(n=1) 
Patient Choice (n=1) 
Discontinued patients 
(n=3) 
Patient choice (n=1) 
Death (n=1) 
Investigator 
recommendation (n=1) 
Discontinued patients 
(n=2) 
Investigator 
recommendation (n=2) 
N=8
Fig. 1. Consort diagram showing the number of patients recruited and those included in the analysis.
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receive open label ibandronate in years 2–5 alongside continued
anastrazole, while 8 with less marked bone loss (LS 1.0%, TH
0.5%) were observed on anastrazole alone.
For those treated with ibandronate, BMD improved on average
during years 2–5 by þ5.01% and þ1.19% at the LS and TH
respectively. Over the 5 years of the study however BMD remained
below baseline measurements at both the LS (2.88%) and TH
(6.22%). At the end of 5 years, 4 patients had T-scores Z2 but in
the other 4 the BMD at either the LS or TH was in the osteoporotic
range.
The 8 patients who were not offered a bisphosphonate experi-
enced relatively little change in BMD throughout the study. At the
end of 5 years, the overall change in BMD from baseline was þ0.15%and 2.72% at the LS and TH respectively. All patients in this group
had an end of treatment BMD T score of 42. Although the
number of patients is small, these results suggest that some patients
are less susceptible to BMD loss from the AI and relatively small
changes in BMD after 2 years appear to predict relatively stable BMD
for the remaining 3 years of AI treatment.
Osteoporotic patients: Nine of the 13 patients initially identiﬁed
as having osteoporosis were assessed at the 5 year visit. These
patients showed steady increases in BMD through the 5 years of
the study. Mean changes in BMD at the LS were þ3.03% and
þ9.65% after 2 and 5 years respectively. At the TH BMD improved
by þ3.18% after 2 years and stabilised at þ2.72% after 5 years.
After 5 years only 2 out of the 9 patients remaining on study still
had a T score of o2.5.
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Fig. 2. Mean percentage change in LS and TH BMD from baseline (95% Conﬁdence Intervals). (A) Ibandronate-Placebo. (B) Placebo-Ibandronate. (C) Osteoporosis.
Table 1
BMD Changes for the 5 years of the study.
Treatment
0–2yrs
Treatment
2–5yrs
N Mean % change from baseline (Range)
0–1 yr 0–2 yrs 2–5 yrs 0–5 yrs
Osteopenic Randomisation Ibandronate Ibandronate 3 LS þ0.23 (3.8,þ2.3) þ0.10 (8.9,þ10.3) þ2.33 (3.7,þ7.3) þ2.60 (7.8,þ18.4)
TH 0.10 (2.1,þ3.4) 2.95 (9.0,þ3.1) 3.08 (6.6,þ0.1) 6.07 (8.9,3.7)
No BP 17 LS þ3.63 (2.3,þ15.1) þ3.71 (6.1,þ19.9) 3.21 (10.9,þ5.6) þ0.29 (10.4,þ17.6)
TH þ1.42 (4.1,þ5.6) þ1.50 (5.8,þ6.9) 5.00 (19.9,þ0.0) 3.71 (16.5,þ3.5)
Placebo Ibandronate 8 LS 2.77 (6.3,þ2.0) 7.06 (16.0,þ0.7) þ5.01 (4.3,þ17.0) 2.88 (15.4,þ17.7)
TH 5.19 (9.9,-0.4) 7.27 (12.3,-4.0) þ1.19 (5.5,þ5.5) 6.22 (10.3,0.1)
No BP 8 LS 1.88 (4.7,þ0.5) 1.00 (4.4, þ3.3) þ1.22 (4.3,þ9.8) þ0.15 (3.5,þ5.0)
TH 0.41 (5.2,þ5.2) 0.52 (5.9,þ7.2) 1.82 (5.4,þ1.5) 2.72 (5.6,þ2.1)
Osteoporosis Ibandronate for 5 yrs 9 LS þ5.94 (þ0.7,þ15.2) þ3.03 (2.3,þ12.1) þ6.43 (þ2.1,þ13.5) þ9.65 (þ4.9,þ18.9)
TH þ3.34 (0.4,þ8.5) þ3.18 (3.7,þ8.1) 0.46 (2.5,þ5.9) þ2.72 (4.0,þ9.6)
BP¼Bisphosphonate.
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with osteopenia through the 5 years of the study. The number of
patients with osteoporosis at either the LS or TH increased from0 to 4 to 7 at the baseline, 2 year and 5 year endpoints respectively.
Six out of the 11 patients (54%) who were offered ibandronate from
2–5 years developed or still had osteoporosis at 5 years.
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Fig. 3. Changes in BMD groupings for all osteopenic patients.
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From 2 to 5 years on study, one patient out of the 21 patients
who were initially randomised to ibandronate withdrew from
the study (patient choice). After 2 years, 19 patients who
were randomised to placebo remained on study. Of these 3 patients
came off study prior to the 5 year visit (patient choice n¼1, death
n¼1, investigator recommendation n¼1). 2 osteoporotic patients
came off study following the 2 year visit (investigator recommenda-
tion n¼2). Three patients withdrew from the study following their
2 year visit due following a recommendation from the treating
clinician. In each of these 3 cases the treatment was discontinued
because of problems related to the anastrozole rather than any
changes in BMD.7. Adverse events
Treatment reported toxicities were similar to those previously
reported [23].
A total of 10 patients developed a fracture following low
energy trauma during the course of the 5 years of the study. Of
these, four patients were initially randomised to ibandronate
(wrist¼1, hip¼3) and three were randomised to placebo
(wrist¼1, shoulder¼1, rib¼1). A further three fractures occurred
in the osteoporotic group (wrist¼1, hip¼1, humerus¼1).
Cancer recurrence rates were very low because most patients
had an excellent prognosis and no patients recruited to the
study were considered for adjuvant chemotherapy. Only 2 patients
developed recurrent disease during the study, both patients
recurred within the ﬁrst 2 years and were osteopenic receiving
placebo. One patient had a local recurrence and the other devel-
oped widespread metastatic disease including bone metastasis.
Tablet counts suggested that patient adherence to monthly
ibandronate was high with greater than 90% of study patients
taking all of their monthly doses.8. Discussion
Bone mineral density monitoring is now an important part of the
management of breast cancer patients treated with an aromatase
inhibitor. Several groups have now published guidance on how best
to monitor and treat patients at risk. In this small study, a strategy of
monitoring and ultimately treating patients who have developed or
who are at risk of developing osteoporosis has proven effective in at
least maintaining bone density over the 5 year course of aromatase
inhibitor therapy. An oral bisphosphonate is therefore a reasonable
option to treat bone loss from an aromatase inhibitor.
Several other studies have addressed the same issue using
different bisphosphonates. The SABRE study randomised breast
cancer patients taking anastrozole with a T-score of between 1
and 2 to risedronate (35 mg weekly) or placebo. After 2 years,
BMD increased by 2.2% at the LS and by 1.8% at the TH [22].
3 large, very similar studies (Z-FAST, ZO-FAST and E-ZO-FAST),
compared the efﬁcacy of 6 monthly intravenous zoledronic acid
given either from the start of AI therapy with letrozole or if there
was either signiﬁcant bone loss or the development of a non-
traumatic fracture in patients taking letrozole for their breast
cancer. In all three studies [20,24–25] immediate zoledronic acid
prevented bone loss. The Z-FAST study has recently published the
ﬁnal results after 5 years of treatment [20], and showed that
treatment with zoledronic acid resulted in a difference in BMD
after 5 years on study at the LS and TH of 8.9% and 6.7%
respectively (po0.0001). These differences appear somewhat
greater than we observed with oral ibandronate, but no direct
comparison of ibandronate and zoledronic acid is planned to
determine whether there are any meaningful differences in the
two treatment approaches.
The ARIBON study has not evaluated BMD changes after the
5 years of aromatase inhibitor therapy but a degree of recovery of
BMD would be expected as was seen in the extended results of
the ATAC [26] and IES [27] trials. Although the small number of
patients and the fact that some patients on placebo required
subsequent bisphosphonate limits our study, some important
conclusions can nevertheless be drawn. Firstly a strategy of
introducing a bisphosphonate in patients with severe osteopenia
can prevent osteoporosis but patients still need to be monitored
for changes in bone density. Secondly patients who have rela-
tively stable BMD for the ﬁrst 2 years of an aromatase inhibitor
without a bisphosphonate may require little further treatment or
monitoring because the risk of subsequent accelerated bone
loss appears to be low. Further research is important to investi-
gate why their bone density is so stable and also how these
patients can be prospectively identiﬁed. Thirdly patients with
osteoporosis at the diagnosis of breast cancer can be safely
treated with an aromatase inhibitor provided they are also
prescribed a bisphosphonate.References
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